LISINOPRIL IMPLICATION IN THE CLINICAL PRACTICE
https://doi.org/10.20996/1819-6446-2010-6-4-21-25
Abstract
The most socially significant cardiovascular diseases are recently considered from the standpoint of "cardiovascular continuum". Changes in neurohumoral factors especially activation of the renin-angiotensin-aldosterone system (RAAS) play a key role in the pathogenesis of the cardiovascular continuum. The first drugs that block RAAS were ACE inhibitors. Lisinopril deserves special attention among the ACE inhibitors. Lisinopril — one of the most known and well-studied drugs in this group with proven organoprotective properties. This allows its use in various clinical situations. Lisinopril is used for hypertension treatment long ago and there are a lot of evidences of its high antihypertensive efficacy currently. Lisinopril provides organ protection in various stages of the cardiovascular continuum and improves the life prognosis in patients with ischemic heart disease and chronic heart failure.
About the Authors
V. I. Podzolkov
I.M. Setchenov First Moscow State Medical University
Russian Federation
Russian Federation
Chair of faculty therapy N2, Medical Faculty
Dovatora ul. 15, Moscow, 119048
A. I. Tarzimanova
I.M. Setchenov First Moscow State Medical University
Russian Federation
Russian Federation
Chair of faculty therapy N2, Medical Faculty
Dovatora ul. 15, Moscow, 119048
References
1. Ezzati M., Hoorn S.V., Rodgers A. et al. Estimates of global and regional potential health gains from reducing multiple majorrisk factors. Lancet 2003;362(9380):271–80.
2. Здравоохранение в России. 2007: статистический сборник. Федеральная служба государственной статистики. М., 2007.
3. Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121(4 Pt 1):1244–63.
4. Dzau V.J., Antman E.M., BlackH.R. et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006;114(25):2850–70.
5. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force fortheManagement of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-87.
6. L pez-Send n J., Swedberg K., McMurray J. et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE–inhibitors ofthe European Society of Cardiology. Eur Heart J 2004;25(16):1454–70.
7. Semple P.F., Cumming A.M., Meredith P.A., Morton J.J. Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man. Cardiovasc Drugs Ther 1987;1(1):45-50.
8. Bull H.G., Thornberry N.A., Cordes M.H. et al. Inhibition of rabbit lung angiotensin-converting enzyme by N alpha-[(S)-1-carboxy-3-phenylpropyl]L-alanyl-L-proline and N alpha-[(S)-1-carboxy-3-phenylpropyl]L-lysyl-L-proline. J Biol Chem 1985;260(5):2952-62.
9. Diamant M., Vincent H.H. Lisinopril versus enalapril: evaluation of trough:peak ratio by ambulatory blood pressure monitoring.JHum Hypertens 1999;13(6):405–12.
10. Os I., Bratland B., Dahl f B. et al. Lisinopril or nifedipine in essential hypertension? A Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients. J Hypertens 1991;9(12):1097-104.
11. Malacco E., Santonastaso M., Vari N.A. et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 2004;26(6):855–65.
12. Davis B.R., Cutler J.A., Gordon D.J. et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996;9(4 Pt 1):342-60.
13. Reisin E., Weir M.R., Falkner B. et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatmentin Obese Patients WithHypertension (TROPHY) Study Group. Hypertension 1997;30(1 Pt 1):140-5.
14. Mancia G., Zanchetti A., Agabiti-Rosei E. et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997; 95(6);1464–70.
15. Terpstra W.F., May J.F., Smit A.J. et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001;19(2):303-9.
16. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997;349(9068): 1787-92.
17. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343(9806):1115-22.
18. Borghi C., Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation–2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: Results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003;145(1):80-7.
19. Packer M., Poole-Wilson P.A., Armstrong P.W. et al. Comparative effects of lowand high doses of the angiotensin-converting inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100(23):2312-8.
Review
For citations:
Podzolkov V.I., Tarzimanova A.I. LISINOPRIL IMPLICATION IN THE CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology. 2010;6(4):565-568. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-4-21-25
Views:
735
Email this article 